Roche subsidiary, Genentech, has announced that the US FDA has accepted its supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery ...
Roche's Perjeta has been launched today in the UK for use in women with HER2-positive breast cancer before surgery – but, as with many new cancer drugs, access to treatment is uncertain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback